Socrates Health Solutions released results of recent human testing. The data, as expected, confirmed the capabilities of the Socrates technology across a broader range of glucose levels in human subjects including diabetics. This data set demonstrates the company’s continued progress towards its end-state of the Socrates Companion design.
April 11, 2018
DALLAS–(BUSINESS WIRE)–